[Skip to Navigation]
Invited Commentary
August 20, 2020

Treating Neovascular Age-Related Macular Degeneration—So Much More to Learn

Author Affiliations
  • 1Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
  • 2Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Australia
JAMA Ophthalmol. 2020;138(10):1051-1052. doi:10.1001/jamaophthalmol.2020.3000

Anti–vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD) has been a resounding success and a breakthrough in the treatment for a disease complication that can devastate lives. As a group, patients do very well, at least for the first few years, if treated sufficiently often to control neovascular activity. However, even when treatments are delivered with appropriate, protocol-directed treatment frequencies, with time, atrophy and fibrosis affect the outcomes and can be associated with loss of visual acuity.1 Understanding the drivers and risk factors for the development of these late complications, which can limit visual acuity outcomes despite successful suppression of the VEGF drive, is critical if we are to limit their effects in an attempt to maintain early visual acuity gains in the long term.

Add or change institution